neuroClues Secures €10 Million in Series A Funding
neuroClues, a French-Belgian MedTech startup, has successfully raised €10 million in a Series A funding round. This investment will bolster their efforts to expand their innovative eye-tracking technology used for diagnosing neurological disorders. The round was led by Teampact Ventures, White Fund, and the EIC Fund, with additional participation from InvestBW, Leansquare, Wallonie Entreprendre, and Olivier Legrain, CEO of IBA.
Company Background
Founded in 2020 by Antoine Pouppez and Pierre Daye, neuroClues has developed an easy-to-use eye-tracking environment that assists medical practitioners in quantifying clinical exams. The company's technology leverages artificial intelligence to analyze eye movements, providing objective biomarkers that aid in the early detection and monitoring of neurological conditions.
"Our goal is to make neurological diagnostics more accessible and accurate," said Antoine Pouppez, Co-Founder and CEO of neuroClues.
Addressing Diagnostic Challenges
The startup's technology addresses significant challenges in the field of neurology, where traditional diagnostic methods often rely on subjective assessments or costly imaging techniques. These conventional approaches can miss early-stage issues, leading to misdiagnoses that neuroClues aims to reduce through its AI-powered system.
Use of Funds
The newly acquired funds are earmarked for scaling the deployment of neuroClues' technology across Europe. This expansion will include enhancing their AI capabilities and increasing production to meet growing demand from healthcare providers seeking more reliable diagnostic tools.
Leadership Team
Alongside CEO Antoine Pouppez, Pierre Daye serves as the Chief Technology Officer, bringing technical expertise to the company's mission of transforming neurological diagnostics.
Future Outlook
With the growing incidence of neurodegenerative diseases globally, neuroClues is positioned to play a vital role in improving diagnostic accuracy and accessibility. The support from prominent investors underscores confidence in the startup's potential to impact the healthcare landscape significantly.
For more information, visit neuroClues.